3 potential blockbusters under FDA review
AbbVie gets the most out of its workers
Where will Bluebird Bio be in one year?
Roche/Exelixis’ Cotellic fizzles in melanoma study
*please scroll down for all the latest news*
*scroll through previous pages at the bottom to get older news*
Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe
